Genetics of lipid traits and relationship to coronary artery disease

Current Cardiology Reports

Volumn 15, Issue 9, 2013, Pages

  Keenan, Tanya E ^a   Rader, Daniel J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Apolipoprotein A5; Apolipoprotein C3; Cholesterol ester transfer protein; Coronary artery disease; Genetics; GWAS; HDL C; LDL C; Lipid traits; Lipids; Lipoprotein lipase; Lipoprotein(a); Mendelian randomization; PCSK9; SORT1; TG; TRIB1

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER; LIPID;

ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; GENE LOCUS; GENETIC TRAIT; GENETIC VARIABILITY; HUMAN; LIPID BLOOD LEVEL; LPA GENE; REVIEW; BLOOD; GENETIC PREDISPOSITION; GENETICS; MENDELIAN RANDOMIZATION ANALYSIS; PROCEDURES; SINGLE NUCLEOTIDE POLYMORPHISM; METHODOLOGY;

BIOLOGICAL MARKERS; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIPIDS; LIPOPROTEIN(A); MENDELIAN RANDOMIZATION ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; TRIGLYCERIDES;

EID: 84885125693     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-013-0396-9     Document Type: Review

References (85)

1. Rader DJ, Daughtery A. Translating molecular discoveries into new therapies for atherosclerosis. Nature. 2008;451:904-13. (Pubitemid 351301745)
2. Rader DJ, Alexander ET, Weibel GL, et al. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res. 2009;50S:189-94.
3. Di Angelantonio E, Sarwar N, et al. Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993-2000.
4. Gotto Jr AM, Moon JE. Recent clinical studies of the effects of lipid-modifying therapies. Am J Cardiol. 2012;110:15A-26.
5. Wierzbicki AS, Clarke RE, Viljoen A, Mikhailidis DP. Triglycerides: a case for treatment? Curr Opin Cardiol. 2012;27:398-404.
6. Rader DJ, Tall AR. The not-so-simple HDL story: is it time to revise the HDL cholesterol hypothesis? Nat Med. 2012;18:1344-6.
7. Ebrahim S, Davey SG. Mendelian randomization: can genetic epidemiology help redress the failures of observational epidemiology? Hum Genet. 2008;123:15-33.
8. •• Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466:707-13. This is the largest GWAS for lipid traits to date with over 100,000 individuals, and it also assessed association of lipid variants with CAD.
9. • Asselbergs FW, Guo Y, van Iperen EP, et al. Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet. 2012;91:823-38. This recent GWAS for lipid traits identified several new loci significantly associated with LDL-C, TG, HDL-C, and/or total cholesterol levels.
10. •• Deloukas P, Kanoni S, et al. The CARDIoGRAMplusC4D Consortium. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2012;45:25-33. The largest GWAS for CAD to date found that over one-quarter of genome-wide significant CAD variants were also genome-wide significantly associated with lipid traits.
11. Kathiresan S, Srivastava D. Genetics of human cardiovascular disease. Cell. 2012;148:1242-57.
12. Rader DJ, Cohen J, Hobbs HH. Monogenic hyperchoelsterolemia: new insights in pathogenesis and treatment. J Clin Invest. 2003;111:1795-803. (Pubitemid 38057721)
13. Marchini J, Howie B. Genotype imputation for genome-wide association studies. Nat Rev Genet. 2010;11:499-511.
14. Lawlor DA, Harbord RM, Sterne JA, et al. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27:1133-63. (Pubitemid 351395448)
15. Strong A, Rader DJ. Clinical implications of lipid genetics for cardiovascular disease. Curr Cardiovasc Risk Rep. 2010;4:461-8.
16. •• Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomization study. Lancet. 2012;380:572-80. The largest Mendelian randomization study of HDL-C and MI found that HDL-C raising genetic variants were not associated with a decreased risk of MI.
17. Whitfield AJ, Barrett PH, van Bockxmeer FM, et al. Lipid disorders and mutations in the APOB gene. Clin Chem. 2004;50:1725-32. (Pubitemid 39298000)
18. Shen H, Damcott CM, Rampersaud E, et al. Familial defective apoplipoprotein B-100 and increased low-density lipoprotein cholesterol and coronary artery calcification in the old order Amish. Arch Intern Med. 2010;170:1850-5.
19. Sankatsing RR, Fouchier SW, de Haan S, et al. Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol. 2005;25:1979-84. (Pubitemid 41243472)
20. Fitzgerald ML, Mujawar Z, Tamehiro N. ABC transporters, atherosclerosis and inflammation. Atherosclerosis. 2010;211:361-70.
21. Hubacek JA, Berge KE, Cohen JC, Hobss HH. Mutations in ATP-cassette binding proteins G5 (ABCG5) and G8 (ABCG8) causing sitosterolemia. Human Mutat. 2001;18:359-60.
22. Lee MH, Lu K, Patel SB. Genetic basis of sitosterolemia. Curr Opin Lipidol. 2001;12:141-9. (Pubitemid 32242921)
23. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154-6. (Pubitemid 36666925)
24. Humphries SE, Whittall RA, Hubbart CS, et al. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet. 2006;43:943-9. (Pubitemid 46080192)
25. Cohen J, Pertsemlidis A, Kotowski IK, et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37:161-5.
26. Cohen JC, Boerwinkle E, Mosley Jr TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264-72.
27. Zhang DW, Lagace TA, Garuti R, et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem. 2007;282:18602-12. (Pubitemid 47100234)
28. Fisher TS, Lo Surdo P, Pandit S, et al. Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation. J Biol Chem. 2007;282:20502-12. (Pubitemid 47100016)
29. Kathiresan S, Voight BF, et al. Myocardial Infarction Genetics Consortium. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet. 2009;41:334-41.
30. Dias CS, Shaywitz AJ, Wasserman SM, et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol. 2012;60:1888-98.
31. • Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012;367:1891-900. This phase 2 randomized trial in patients with primary hypercholesterolemia showed that a PCSK9 monoclonal antibody added to a statin decreased LDL-C more than the statin alone.
32. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomized controlled trial. Lancet. 2012;380:29-36.
33. Kathiresan S, Melander O, Guiducci C, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet. 2008;40:189-97. (Pubitemid 351171402)
34. Samani NJ, Erdmann J, Hall AS, et al. Genomewide association analysis of coronary artery disease. N Engl J Med. 2007;357:443-53. (Pubitemid 47204873)
35. •• Musunuru K, Strong A, Frank-Kamenetsky M, et al. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature. 2010;466:714-9. This translational study demonstrated a functional mechanism by which a GWAS-identified lipid variant associated with CAD alters LDL-C levels.
36. Strong A, Ding Q, Edmondson AC, et al. Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism. J Clin Invest. 2012;122:2807-16.
37. Reilly MP, Li M, He J, et al. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: 2 genome-wide association studies. Lancet. 2011;377:383-92.
38. Campos M, Sun W, Yu F, et al. Genetic determinants of plasma von Willebrand factor antigen levels: a target gene SNP and haplotype analysis of ARIC cohort. Blood. 2011;117:5224-30.
39. Zhang H, Mooney CJ, Reilly MP. ABO blood groups and cardiovascular diseases. Int J Vasc Med. 2012;2012:641917.
40. Siest G, Pillot T, Regis-Bailly A, et al. Apolipoprotein E: an important gene and protein to follow in laboratory medicine. Clin Chem. 1995;41:1068-86.
41. Mahley RW, Rall SC. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000;1:507-37.
42. Knouff C, Hinsdale ME, Mezdour H, et al. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J Clin Invest. 1999;103:1579-86.
43. van Dijk KW, Rensen PC, Voshol PJ, Havekes LM. The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism? Curr Opin Lipidol. 2004;15:239-46. (Pubitemid 38716555)
44. O'Brien PJ, Alborn WE, Sloan JH, et al. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin Chem. 2005;51:351-9. (Pubitemid 40175805)
45. Shachter NS. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol. 2001;12:297-304. (Pubitemid 32521955)
46. Sundaram M, Zhong S, Bou Khalil M, et al. Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions. J Lipid Res. 2010;51:150-61.
47. Jong MC, Rensen PC, Dahlmans VE, et al. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. J Lipid Res. 2001;42:1578-85. (Pubitemid 33026056)
48. Merkel M, Loeffler B, Kluger M, et al. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem. 2005;280:21553-60. (Pubitemid 40805722)
49. Schaap FG, Rensen PC, Voshol PJ, et al. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J Biol Chem. 2004;279:27941-7. (Pubitemid 38900062)
50. Ito Y, Azrolan N, O'Connell A, et al. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science. 1990;249:790-3.
51. van der Vliet HN, Schaap FG, Levels JH, et al. Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. Biochem Biophys Res Commun. 2002;295:1156-9.
52. Varbo A, Benn M, Tybjaerg-Hansen A, et al. TRIB1 and GCKR polymorphisms, lipid levels, and risk of ischemic heart disease in the general population. Arterioscler Thromb Vasc Biol. 2011;31:451-7.
53. • Burkhardt R, Toh SA, Lagor WR, et al. Trib1 is a lipid- and myocardial infarction-associated gene that regulates hepatic lipogenesis and VLDL production in mice. J Clin Invest. 2010;120:4410-4. Motivated by GWAS results, this study found that overexpression of hepatic TRIB1 decreased plasma TG in mice and that TRIB1 knockout mice demonstrated increased plasma TG, suggesting that the TRIB1 gene is a novel regulator of TG metabolism.
54. Mattijssen F, Kersten S. Regulation of triglyceride metabolism by angiopoietin-like proteins. Biochim Biophys Acta. 1821;2012:782-9.
55. • Musunuru K, Pirruccello JP, Do R, et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med. 2010;363:2220-7. This exome sequencing study identified 2 nonsense mutations in ANGPTL3 that influence lipid metabolism.
56. Shimizugawa T, Ono M, Shimamura M, et al. ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J Biol Chem. 2002;277:33742-8.
57. Shan L, Yu XC, Liu Z, et al. The angiopoietin-like proteins ANGPTL3 and ANGPTL4 inhibit lipoprotein lipase activity through distinct mechanisms. J Biol Chem. 2009;284:1419-24.
58. Koster A, Chao YB, Mosior M, et al. Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism. Endocrinology. 2005;146:4943-50. (Pubitemid 41446633)
59. Kirchgessner TG, LeBoeuf RC, Langner CA, et al. Genetic and developmental regulation of the lipoprotein lipase gene: loci both distal and proximal to the lipoprotein lipase structural gene control enzyme expression. J Biol Chem. 1989;264:1473-82. (Pubitemid 19050983)
60. Havel RJ. Triglyceride-rich lipoproteins and plasma lipid transport. Arterioscler Thromb Vasc Biol. 2010;30:9-19.
61. Myers Jr MG, Sun XJ, White MF. The IRS-1 signaling system. Trends Biochem Sci. 1994;19:289-93. (Pubitemid 24221949)
62. Rung J, Cauchi S, Albrechtsen A, et al. Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. Nat Genet. 2009;41:1110-5.
63. Sim E, Fakis G, Laurieri N, Boukouvala S. Arylamine N-acetyltransferases- from drug metabolism and pharmacogenetics to identification of novel targets for pharmacological intervention. Adv Pharmacol. 2012;63:169-205.
64. Rader DJ, de Goma EM. Approach to the patient with extremely low HDL-cholesterol. J Clin Endocrinol Metab. 2012;97:3399-407.
65. Rader DJ. Regulation of reverse cholesterol transport and clinical implications. Am J Cardiol. 2003;92:42J-9.
66. de Lemos AS, Wolfe ML, Long CJ, et al. Identification of genetic variants in endothelial lipase in persons with elevated high-density lipoprotein cholesterol. Circulation. 2002;106:1321-6. (Pubitemid 35424731)
67. Edmondson AC, Brown RJ, Kathiresan S, et al. Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. J Clin Invest. 2009;119:1042-50.
68. • Haase CL, Tybjaerg-Hansen A, Qayyum AA, Schou J, Nordestgaard BG, Frikke-Schmidt R. LCAT, HDL cholesterol, and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals. J Clin Endocrinol Metab. 2012;97:248-56. This Mendelian randomization study showed that a lecithin-cholesterol acyltransferase variant was significantly associated with decreased HDL-C levels but not with increased risk of MI.
69. Johannsen TH, Kamstrup PR, Andersen RV, et al. Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease. J Clin Endocrinol Metab. 2009;94:1264-73.
70. Andersen RV, Wittrup HH, Tybjaerg-Hansen A, et al. Hepatic lipase mutations, elevated high-density lipoprotein cholesterol, and increased risk of ischemic heart disease: the Copenhagen city heart study. J Am Coll Cardiol. 2003;41:1972-82. (Pubitemid 36677118)
71. Frikke-Schmidt R, Nordestgaard BG, Stene MC, et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA. 2008;299:2524-32. (Pubitemid 351787208)
72. Frikke-Schmidt R, Nordestgaard BG, Jensen GB, et al. Genetic variation in ABCA1 predicts ischemic heart disease in the general population. Arterioscler Thromb Vasc Biol. 2008;28:180-6.
73. Thompson A, Di Angelantonio E, Sarwar N, et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 2008;299:2777-88. (Pubitemid 351846853)
74. Boekholdt SM, Sacks FM, Jukema JW, et al. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation. 2005;111:278-87. (Pubitemid 40165333)
75. Larach DB, de Goma EM, Rader DJ. Targeting high density lipoproteins in the prevention of cardiovascular disease? Curr Cardiol Rep. 2012;14:684-91.
76. • Tsimikas S, Hall JL. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol. 2012;60:716-21. This review summarizes in detail the leading hypothesized mechanisms linking Lp(a) to cardiovascular disease.
77. Lamon-Fava S, Jimenez D, Christian JC, et al. The NHLBI Twin Study: heritability of apolipoprotein A-I and B, and low density lipoprotein subclasses and concordance for lipoprotein(a). Atherosclerosis. 1991;91:97-106.
78. Kronenberg F, Utermann G. Lipoprotein(a): resurrected by genetics. J Intern Med. 2012;273:6-30.
79. Li KM, Wilcken DE, Dudman NP. Effect of serum lipoprotein (a) on estimation of low-density lipoprotein cholesterol by the Friedewald formula. Clin Chem. 1994;40:571-3. (Pubitemid 24116105)
80. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361:2518-28.
81. Dube JB, Boffa MB, Hegele RA, Koschinsky ML. Lipoprotein(a): more interesting than ever after 50 years. Curr Opin Lipidol. 2012;23:133-40.
82. • Li Y, Luke MM, Shiffman D, Devlin JJ. Genetic variants in the apolipoprotein(a) gene and coronary heart disease. Circ Cardiovasc Genet. 2011;4:565-73. This meta-analysis found that 2 SNPs in the LPA gene are independently associated with Lp(a) levels and CAD.
83. Helgadottir A, Gretarsdottir S, Thorleifsson G, et al. Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol. 2012;60:722-9.
84. Bergmark C, Dewan A, Orsoni A, et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res. 2008;49:2230-9.
85. Seimon TA, Nadolski MJ, Liao X, et al. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab. 2010;12:467-82.